Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01155492|
Recruitment Status : Completed
First Posted : July 1, 2010
Last Update Posted : May 30, 2013
|Condition or disease|
|Parkinson's Disease Multiple System Atrophy|
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Observational Model:||Case Control|
|Official Title:||Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||February 2013|
Subjects with Parkinson's disease
Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
Age- and gender-matched subjects who do not have Parkinson's disease
Multiple system atrophy.
Men and women with clinically diagnosed multiple system atrophy.
- Total urine sugar per 24 hours [ Time Frame: 24 hours ]Subjects consume a mixture of sugars (lactulose, sucrose), then collect urine for 24 hours. Sugar concentrations in the urine are assayed by gas chromatography.
- LH-PCR fingerprint analysis [ Time Frame: 24 hours ]Total genomic DNA will be extracted from colonic mucosa biopsy specimens and lumenal samples, and will be amplified by PCR using bacterial primers. PCR products will be separated and analyzed for amplicon length heterogeneity.
- Blood endotoxin and cytokine levels [ Time Frame: 24 hours ]Blood endotoxin and cytokine levels
- Histopathology and immunohistochemistry of colonic mucosa [ Time Frame: 24 hours ]A portion of the colonic tissue will be studied with histopathology and immunohistochemistry techniques for alpha-synuclein pathology, cytokines and inflammatory markers.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01155492
|United States, Illinois|
|Rush University Medical Center|
|Chicago, Illinois, United States, 60612|
|Principal Investigator:||Kathleen M Shannon, M.D.||Rush University Medical Center|